Hims & Hers Health Inc. (HIMS) stock surged 5.15% in Tuesday's pre-market session, following Morgan Stanley's initiation of coverage on the telemedicine company with an Overweight rating.
Morgan Stanley analysts see significant growth potential for the company, which provides direct-to-consumer healthcare services, including prescriptions and over-the-counter products. The brokerage firm set a price target of $26.77 on Hims & Hers Health, implying an upside of over 50% from the stock's current levels.
The bullish initiation from Morgan Stanley has fueled investor optimism about Hims & Hers Health's prospects, driving the stock's strong pre-market rally. The company's innovative telehealth model and growing product portfolio have positioned it well to capitalize on the burgeoning digital healthcare market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。